Phase I pharmacotoxicology study of human fibroblast interferon in human cancers.
Twelve patients with advanced cancer were treated with human fibroblast interferon. Interferon administered im in doses up to 10 x 10(6) U three times weekly for 2 weeks was associated with highly variable, but detectable, plasma levels. Bolus interferon given iv was associated with a reproducible, immediate peak of activity followed by a rapid loss of detectable activity. Continuous infusion of interferon over 2 hours resulted in a slowly increasing dose-related level to a maximum near the end of the infusion followed by a loss of detectable activity for about 1 hour following infusion. Interferon administered both im and iv caused a mild, easily tolerated pyrexia as the only regularly occurring side effect. In 1 patient interferon treatment suppressed a malignant clone of circulating blasts trisomic for chromosomes No. 8 and 21 from 59 to 0%.
D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D007273:Injections, Intramuscular; D007372:Interferons / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013489:Suppression, Genetic; D013997:Time Factors; D014314:Trisomy
D007372:Interferons